TARA Protara Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1359931 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-48.3%
TTM EPS YoY-0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-57.4%
ROA-52.1%
ROIC (approx.)-57.3%
Asset turnover—
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.00x
Current ratio9.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $42.63M | $31.70M |
| SG&A expense | $21.92M | $17.45M |
| Operating income | -$64.55M | -$49.15M |
| Pretax income | $57.35M | $44.56M |
| Net income | -$57.44M | -$44.60M |
| EBITDA | -$64.19M | -$48.82M |
| EPS (basic) | -1.34 | -2.17 |
| EPS (diluted) | -1.34 | -2.17 |
| Weighted avg. shares (diluted) | 42.84M | 20.59M |
| Balance sheet | ||
| Cash & equivalents | $49.66M | $163.54M |
| Short-term investments | $105.90M | $7.49M |
| Current assets | $159.50M | $172.16M |
| PP&E, net | $759,000 | $1.03M |
| Total assets | $209.47M | $181.45M |
| Current liabilities | $10.94M | $10.96M |
| Total liabilities | $13.06M | $14.32M |
| Shareholders' equity | $196.41M | $167.13M |
| Shares outstanding | 53.59M | 35.04M |
| Cash flow statement | ||
| Operating cash flow | -$56.37M | -$35.81M |
| Capital expenditure | $94,000 | $63,000 |
| Free cash flow | -$56.46M | -$35.87M |
| Investing cash flow | -$139.49M | $19.16M |
| Financing cash flow | $82.72M | $139.87M |
| Depreciation & amortization | $362,000 | $332,000 |
| Stock-based compensation | $3.83M | $4.12M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.